Guntur clinicians have reported the successful use of bacteriophage therapy to treat a carbapenem‑resistant infection of an artificial knee joint, marking a significant clinical milestone in the management of drug‑resistant prosthetic joint infections locally and nationally.
Case details and clinical team
Doctors at Samishta Hospital (SHRI) in Guntur treated a 72‑year‑old man whose artificial knee had been infected by Pseudomonas aeruginosa resistant to carbapenems and other antibiotics. The intervention, described in a case report published on 22 October 2026 in the International Journal of Infectious Diseases (IJID Regions), involved direct intra‑articular delivery of a bacteriophage preparation over 10 days.
Researchers at the phage laboratory of SRM University in Andhra Pradesh developed a cocktail containing three specific lytic bacteriophages targeted to the infecting strain. The clinical intervention was led by Dr Kalyan Chakravarthy Koganti, according to the published report.
Therapeutic rationale and outcome
Bacteriophages are viruses that infect and lyse bacteria, often exhibiting narrow host range that requires identification of the causative organism before therapy. In this case, joint‑fluid testing and culture identified carbapenem‑resistant Pseudomonas aeruginosa, prompting the selection of matching phages for the cocktail.
The phage cocktail was administered directly into the infected joint daily for 10 days. Follow‑up clinical and microbiological assessments in June 2026 showed no growth in joint‑fluid culture and the patient remained healthy and antibiotic‑free at the time of reporting.
"This case represents India’s first reported successful use of phage therapy for a carbapenem‑resistant artificial joint infection," the IJID Regions report stated.
Local context and wider significance
Prosthetic joint infections are a serious complication after orthopaedic surgery and become increasingly difficult to treat when caused by multidrug‑resistant organisms such as carbapenem‑resistant Pseudomonas. For Guntur and surrounding districts, where orthopaedic procedures are common, alternative therapies that can address antibiotic resistance may reduce morbidity, prolonged hospital stays and repeat surgeries.
SRM University investigators have earlier collaborated with local clinicians: the report also notes a separate 2025 case at SHRI in which a 72‑year‑old woman from Bapatla with a chronic bone and joint infection due to multidrug‑resistant Acinetobacter baumannii had no recurrence during six months of follow‑up after phage treatment.
- Agent used: three‑phage cocktail developed at SRM University phage laboratory.
- Delivery: direct intra‑articular administration over 10 days.
- Organism: carbapenem‑resistant Pseudomonas aeruginosa.
Implications for practice and policy
The case underscores the importance of laboratory capacity to identify causative bacteria and to screen for suitable phages, a requirement because phages typically target specific strains. Wider clinical adoption would depend on regulatory frameworks, validated production pipelines, standardised susceptibility testing for phages and controlled clinical trials to establish safety and efficacy beyond single case reports.
For Guntur hospitals, the report highlights potential complementary options for managing intractable device‑related infections, particularly when conventional antibiotics fail. Health administrators and clinicians will need to weigh operational challenges such as phage sourcing, bedside delivery protocols and long‑term follow‑up against the benefits in individual refractory cases.
| Item | Detail |
|---|---|
| Patient age | 72 years |
| Pathogen | Pseudomonas aeruginosa (carbapenem‑resistant) |
| Therapy | Three‑phage cocktail, intra‑articular, 10 days |
| Outcome | No growth on follow‑up culture (June 2026); patient healthy and antibiotic‑free |
The findings were reported in IJID Regions on 22 October 2026. Local clinicians and researchers say the case adds to growing international interest in bacteriophage therapy as a targeted tool against antibiotic‑resistant bacterial infections, while emphasising the need for structured evidence and regulatory oversight before routine use.
